ClinicalTrials.gg
RecruitingNCT05933031Updated Jul 6, 2023

Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients

A Phase 2 interventional study of Tegoprazan 50 mg Triple Therapy and Tegoprazan 100 mg Triple Therapy in Helicobacter Pylori Infection, sponsored by HK inno.N Corporation. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-06.

Sponsored by HK inno.N Corporation · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
381
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

This exploratory study is designed to compare safety and efficacy between a Tegoprazan dose-specific standard triple therapy and Lansoprazole standard triple therapy in H. pylori positive patients.

Read the detailed description

A Randomized, Double-Blind, Active-controlled, Multicenter, Therapeutic Exploratory Study to to Evaluate the Safety and Efficacy of a Standard Triple Therapy with Tegoprazan and Lansoprazole standard triple therapy in H. pylori Positive Patients, twice a day for 14 days.

02

Conditions studied

  • Helicobacter Pylori Infection
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • H. pylori positive at screening
  • Subjects who have upper gastrointestinal disease

Exclusion criteria

Exclusion Criteria:

  • Having received prior therapy for eradication of H. pylori
  • Prior use of P-CAB, proton pump inhibitors (PPIs), H2 receptor blockers within 14 days
  • Prior use of H. pylori eradication effective antibiotics, bismuth within 28 days
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
381 participants (estimated)

Study arms

  • Experimental
    Tegoprazan 50 mg

    Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days

    Drug: Tegoprazan 50 mg Triple Therapy

  • Experimental
    Tegoprazan 100 mg

    Tegoprazan 100 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days

    Drug: Tegoprazan 100 mg Triple Therapy

  • Active comparator
    Lansoprazole

    Lansoprazolee/Clarithromycin/ Amoxicillin BID peroral, 14 days

    Drug: Lansoprazole Triple Therapy

Interventions

06

What researchers measure

Primary outcomes

  1. H. pylori eradication rate

    Assess H. pylori eradication rate by UBT

    Time frame: 42 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Dec 2024, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2023
First posted
Jul 6, 2023
StartActual
Feb 27, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Jul 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05933031
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Feb 27, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jul 6, 2023

Study contacts

Eun Ji Kim
Contact
eunji.kim24@inno-n.com
82-2-6477-0290
Hee Hyun Kim
Contact
heehyun.kim@inno-n.com
82-2-6477-0258
Jae Gyu Kim
principal investigator · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion